News & Updates
Filter by Specialty:

Navitoclax–ruxolitinib combo doubles spleen response rates in myelofibrosis
17 Aug 2024
byJairia Dela Cruz
In untreated myelofibrosis, using navitoclax in combination with ruxolitinib appears to result in a twofold increase in the number of patients experiencing spleen volume shrinkage, regardless of prognosis, according to updated data from the phase III TRANSFORM-1 trial.
Navitoclax–ruxolitinib combo doubles spleen response rates in myelofibrosis
17 Aug 2024
Multiple factors influence risks of cirrhosis, HCC in veterans with MAFLD
17 Aug 2024
byStephen Padilla
The incidence of cirrhosis and hepatocellular carcinoma (HCC) among veterans differs according to demographic and clinical characteristics, with the lowest rate seen among Asians, reports a study.
Multiple factors influence risks of cirrhosis, HCC in veterans with MAFLD
17 Aug 2024
AI improves physician accuracy in identifying prostate cancer extent
16 Aug 2024
byStephen Padilla
Use of artificial intelligence (AI)-assisted cancer contours helps minimize underestimation of the extent of prostate cancer, thereby improving the physician’s ability in terms of contouring accuracy and negative margin rate, a study has shown.